tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DocGo (DCGOResearch Report), Kezar Life Sciences (KZRResearch Report) and Biohaven Ltd. (BHVNResearch Report) with bullish sentiments.

DocGo (DCGO)

In a report released today, David Larsen from BTIG maintained a Buy rating on DocGo, with a price target of $13.00. The company’s shares closed last Friday at $6.01.

According to TipRanks.com, Larsen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 30.5% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Privia Health Group, and P3 Health Partners.

Currently, the analyst consensus on DocGo is a Strong Buy with an average price target of $12.40, representing an 119.5% upside. In a report issued on November 20, Northland Securities also maintained a Buy rating on the stock with a $16.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Kezar Life Sciences (KZR)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Kezar Life Sciences today and set a price target of $20.00. The company’s shares closed last Friday at $0.84, close to its 52-week low of $0.67.

According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -6.9% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and MoonLake Immunotherapeutics.

Kezar Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $11.00.

Biohaven Ltd. (BHVN)

BTIG analyst Thomas Shrader maintained a Buy rating on Biohaven Ltd. yesterday and set a price target of $37.00. The company’s shares closed last Friday at $33.66, close to its 52-week high of $33.99.

According to TipRanks.com, Shrader is a 1-star analyst with an average return of -1.8% and a 34.6% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and ProMIS Neurosciences.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Ltd. with a $34.20 average price target, representing a 3.0% upside. In a report issued on November 20, J.P. Morgan also assigned a Buy rating to the stock with a $32.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DCGO:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles